● RADIOAdvertise with us
DOWNUNDERVOICESAustralia · New Zealand · World
Back to Australia
Australia

6 October 2026

Australia's CSL inks $1.2 B deal with Swiss firm Alentis to develop lixudebart for rare kidney and liver diseases treatment

Downunder Voices Newsroom

Australia's CSL inks $1.2 B deal with Swiss firm Alentis to develop lixudebart for rare kidney and liver diseases treatment

Australia's CSL inks $1. 2 B deal with Swiss firm Alentis to develop lixudebart for rare kidney and liver diseases treatment ...

About this report

This article contains independently written commentary and community perspective from Downunder Voices.

Join our community

Follow Downunder Voices

Join thousands of readers following news and community stories from Australia, New Zealand and the Pacific.

More from Australia

View category

Read Next

View latest